We are live on ! Find out more
PM

Prosight Management Portfolio holdings

AUM $610M
1-Year Est. Return 40.86%
This Fund
S&P 500
This Quarter Est. Return
+6.3%
1 Year Est. Return
+40.86%
3 Year Est. Return
+46.17%
5 Year Est. Return
+1.2%
10 Year Est. Return
–
AUM
$183M
AUM Growth
-$3.29M
Cap. Flow
-$8.67M
Cap. Flow %
-4.73%
Top 10 Hldgs %
62.72%
Holding
56
New
18
Increased
15
Reduced
7
Closed
16

Top Buys

Rank Stock Value
1
TNET icon
TriNet
TNET
+$5.38M
2
OPCH icon
Option Care Health
OPCH
+$4.81M
3
MGTX icon
MeiraGTx Holdings
MGTX
+$3.64M
4
NTLA icon
Intellia Therapeutics
NTLA
+$3.43M
5
HCAT icon
Health Catalyst
HCAT
+$3.36M

Top Sells

Rank Stock Value
1
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
+$17.7M
2
CRL icon
Charles River Laboratories
CRL
+$6.54M
3
THC icon
Tenet Healthcare
THC
+$5.26M
4
JNJ icon
Johnson & Johnson
JNJ
+$5.18M
5
ALKS icon
Alkermes
ALKS
+$3.84M

Sector Composition

Rank Sector Weight
1 Healthcare 93.56%
2 Industrials 2.88%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
LKFT
1
Lakefront Biotherapeutics American Depositary Shares
LKFT
$1.82B
$20.6M 11.25%
465,000
+60,000
+15% +$2.52M
PRTA icon
2
Prothena Corp
PRTA
$458M
$19.9M 10.84%
330,000
+8,907
+3% +$522K
KZR
3
DELISTED
Kezar Life Sciences
KZR
$12.4M 6.74%
175,443
+42,653
+32% +$3.16M
MGTX icon
4
MeiraGTx Holdings
MGTX
$1.09B
$10.7M 5.81%
1,633,546
+530,181
+48% +$3.64M
ALBO
5
DELISTED
Albireo Pharma Inc
ALBO
$10.5M 5.74%
486,726
-4,518
-0.9% -$95.5K
HZNP
6
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
$10.2M 5.59%
90,000
-213,000
-70% -$17.7M
ALKS icon
7
Alkermes
ALKS
$8.82B
$8.92M 4.87%
341,521
-160,629
-32% -$3.84M
HUM icon
8
Humana
HUM
$46.7B
$8.84M 4.82%
17,253
+4,453
+35% +$2.34M
ORIC icon
9
Oric Pharmaceuticals
ORIC
$1.25B
$6.95M 3.79%
1,180,000
+243,666
+26% +$823K
MIRM icon
10
Mirum Pharmaceuticals
MIRM
$6.89B
$6.02M 3.28%
308,776
+23,776
+8% +$470K
ALDX icon
11
Aldeyra Therapeutics
ALDX
$91.7M
$5.98M 3.26%
858,709
-352,091
-29% -$2.01M
TNET icon
12
TriNet
TNET
$2.84B
$5.29M 2.88%
+78,000
New +$5.38M
CUE icon
13
Cue Biopharma
CUE
$135M
$5.25M 2.86%
61,350
+9,831
+19% +$899K
STTK icon
14
Shattuck Labs
STTK
$710M
$4.86M 2.65%
2,113,493
+992,717
+89% +$2.49M
OPCH icon
15
Option Care Health
OPCH
$3.4B
$4.66M 2.54%
+154,898
New +$4.81M
QDEL icon
16
QuidelOrtho
QDEL
$1.09B
$4.28M 2.34%
50,000
-12,900
-21% -$1.09M
KALV
17
DELISTED
KalVista Pharmaceuticals
KALV
$4.2M 2.29%
621,667
+91,605
+17% +$491K
HCAT icon
18
Health Catalyst
HCAT
$154M
$3.7M 2.02%
+347,724
New +$3.36M
ABCL icon
19
AbCellera Biologics
ABCL
$1.62B
$3.27M 1.78%
322,754
+236,250
+273% +$2.73M
LENZ
20
LENZ Therapeutics
LENZ
$172M
$3.04M 1.66%
130,937
+80,016
+157% +$1.85M
UNH icon
21
UnitedHealth
UNH
$382B
$2.65M 1.45%
+5,000
New +$2.65M
NTLA icon
22
Intellia Therapeutics
NTLA
$1.5B
$2.52M 1.37%
+72,116
New +$3.43M
CSII
23
DELISTED
Cardiovascular Systems, Inc.
CSII
$1.99M 1.08%
+145,916
New +$2.03M
OSH
24
DELISTED
Oak Street Health, Inc.
OSH
$1.81M 0.99%
+84,000
New +$1.76M
ADCT icon
25
ADC Therapeutics
ADCT
$146M
$1.78M 0.97%
463,310
+215,680
+87% +$862K
1
2 3

Similar funds

PL
Pandi LLC Leawood, Kansas $610M AUM 14.97% 1-Year Est. Return
BFC
Blue Fin Capital Warren, Rhode Island $610M AUM 26.46% 1-Year Est. Return
DCM
DGS Capital Management Jersey City, New Jersey $609M AUM 44.78% 1-Year Est. Return
SAM
Strategy Asset Managers Pasadena, California $609M AUM 32.56% 1-Year Est. Return
CBB
Citizens Business Bank Ontario, California $610M AUM 27.86% 1-Year Est. Return
AIG
American International Group New York $609M AUM 23.67% 1-Year Est. Return
FFWA
FRG Family Wealth Advisors Bellevue, Washington $611M AUM 25.92% 1-Year Est. Return
CIP
Convergence Investment Partners Palm Beach Gardens, Florida $611M AUM 61.48% 1-Year Est. Return

Prosight Management's Q4 2022 Portfolio in Review

As of Q4 2022, Prosight Management held 56 positions worth $183M, down 1.8% from $187M the previous quarter. Its ten largest holdings account for 63% of the portfolio.

Prosight Management withdrew a net $8.67M in Q4 2022, closing 16 positions and reducing 7 holdings. Its most notable exit was Charles River Laboratories, an estimated $6.54M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 94% of assets, down from 97% a quarter earlier, followed by Industrials.

Against the trend, Prosight Management opened a new position in TriNet worth $5.29M.

  • Prosight Management's largest Q4 2022 buy was TriNet: 78,000 shares worth $5.29M.
  • Prosight Management added most to MeiraGTx Holdings in Q4 2022, an estimated $3.64M increase.
  • Prosight Management's biggest Q4 2022 reduction was Horizon Therapeutics Public Limited Company Ordinary Shares, cutting an estimated $17.7M.
  • Prosight Management fully exited Charles River Laboratories in Q4 2022, selling an estimated $6.54M.
  • Prosight Management's ten largest holdings make up 63% of its $183M portfolio in Q4 2022.
  • Prosight Management opened 18 new positions and closed 16 in Q4 2022.
  • Prosight Management's portfolio value fell 1.8% quarter-over-quarter to $183M.

Based on Prosight Management's 13F filing for Q4 2022, filed 14 Feb 2023.